Hetero Labs Limited Montelukast Export Data — India (DGFT 2022–2026)

Name: Hetero Labs Limited Montelukast Export Records India — #7 Exporter, 58 Shipments, $2.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Montelukast

India Pharmaceutical Trade Intelligence

$168.3M510 Suppliers138 CountriesHS 30049099

ExportsIndia → UNITED STATES58.1%India → PHILIPPINES7.9%

ImportsUNITED STATES → India$7.2K MALTA → India$6.9K

#1 Buyer: AMERISOURCE HEALTH

Hetero Labs Limited — Montelukast Exporter #7 | $2.9M Trade Value | TransData Nexus | TransData Nexus

Hetero Labs Limited — Montelukast Exporter Profile

Indian Pharmaceutical Exporter · #7 for Montelukast · $2.9M export value · DGFT Verified

Hetero Labs Limited is the #7 Indian exporter of Montelukast with $2.9M in export value and 58 verified shipments. Hetero Labs Limited holds a 1.7% market share in Montelukast exports across 8 countries. The company exports 46 pharmaceutical products worth $319.3M across 18 therapeutic categories.

Hetero Labs Limited — Montelukast Export Profile: Buyers & Destinations

Hetero Labs Limited Montelukast export treemap — buyers and destination countries | TransData Nexus

Where Does Hetero Labs Limited Export Montelukast?

Country	Value	Shipments	Share
UNITED STATES OF AMERICA	$1.5M	40	86.2%
COLOMBIA	$77.2K	7	4.5%
PANAMA	$50.0K	1	2.9%
NETHERLANDS	$50.0K	1	2.9%
HONG KONG	$21.7K	1	1.3%

Who Are the Top Buyers of Montelukast from Hetero Labs Limited?

Buyer	Country	Value	Orders
XXMBEXXPHAXXACEXXICAXX IXX	UNITED STATES OF AMERICA	$1.4M	39
XXVENXXHARXX PAXXMA XXA	PANAMA	$50.0K	1
XXALLXXT PXXRMAXXUTIXXLS XXALTXXLLC	UNITED STATES OF AMERICA	$50.0K	1
XXAROXXPHAXXA BXX	NETHERLANDS	$50.0K	1
TO THE ORDER OF	NICARAGUA	$49.8K	9
XXTERXXFZCX	COLOMBIA	$44.6K	2
XXC (XXNG XXNG)XXIMIXXD	HONG KONG	$21.7K	1
XXAROXXPHAXXA SXX DXXC VX	MEXICO	$12.4K	1
TO THE ORDER OF .	COLOMBIA	$6.1K	1

Hetero Labs Limited supplies Montelukast to 9 buyers globally. The largest buyer is XXMBEXXPHAXXACEXXICAXX IXX (UNITED STATES OF AMERICA), followed by XXVENXXHARXX PAXXMA XXA (PANAMA) and XXALLXXT PXXRMAXXUTIXXLS XXALTXXLLC (UNITED STATES OF AMERICA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Montelukast Formulations Does Hetero Labs Limited Export?

Product Description / Formulation	Value	Shipments
MONTELUKAST SODIUM 10MG TABLETS	$1.4M	32
MONTELUKAST SODIUM 4MG TABLETS	$159.5K	10
MONTELUKAST SODIUM 4MG TABLETS (1X90'S)	$38.9K	2
MONTELUKAST SODIUM TABLET Batch Nos MNA250201 MNA250202	$21.0K	2
MONTELUKAST SODIUM 5MG TABLETS	$18.6K	1
MONAST MONTELUKAST SODIUM TABLET 7968 BOX 239040 TABLET BATCH NOS MEN250201 MFG DATE FEB 2025 EXP DATE JAN 2027	$11.0K	1
MONTELUKAST SODIUM TABLET	$6.1K	1
MONTELUKAST SODIUM TABLET Batch Nos MNA250202	$5.5K	2
MONTELUKAST SODIUM 4MG TABLETS (1X30'S)	$4.6K	1
MONAST MONTELUKAST SODIUM TABLET 4977BOX 149310 TABLET BATCH NOS MEN250201 MEN250202 MFG DT FEB 25 EXP DT JAN 27	$4.4K	1

Hetero Labs Limited exports 15 distinct Montelukast formulations including tablets, capsules, syrups, and combination drugs. The top formulation is MONTELUKAST SODIUM 10MG TABLETS with 32 shipments worth $1.4M.

How Does Hetero Labs Limited Compare to Nearest Montelukast Exporters?

Exporters ranked immediately above and below #7 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
11	TORRENT PHARMACEUTICALS LIMITED	$3.1M	77	13	$39.7K
9	INDOCO REMEDIES LIMITED	$3.0M	61	2	$50.0K
7	HETERO LABS LIMITED ★	$2.9M	58	8	$50.0K
12	DR REDDYS LABORATORIES LIMITED	$2.3M	45	3	$50.0K
14	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$1.9M	106	6	$17.5K

Hetero Labs Limited ranks #7 among 510 Indian Montelukast exporters. Average shipment value of $50.0K compared to the market average of $144.3K. The closest competitors by value are TORRENT PHARMACEUTICALS LIMITED and INDOCO REMEDIES LIMITED.

Which Indian Ports Ship Montelukast Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	537	8.4%
NHAVA SHEVA SEA (INNSA1)	528	8.2%
SAHAR AIR	479	7.4%
SAHAR AIR CARGO ACC (INBOM4)	466	7.2%
DELHI AIR	451	7.0%
JNPT/ NHAVA SHEVA SEA	286	4.4%
JNPT	224	3.5%
MUNDRA SEA	214	3.3%

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Montelukast Exports

The current geopolitical climate presents both challenges and opportunities for Hetero Labs Limited. The Israel-Iran tensions have led to increased risks in the Red Sea shipping routes, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Hetero, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.

Conversely, the U.S.-China trade tensions have created openings for Indian pharmaceutical companies. The U.S. has imposed tariffs as high as 245% on APIs from certain countries, leading to a reshoring of pharmaceutical manufacturing. Indian firms, including Hetero, have responded by investing in U.S. facilities, with outbound foreign direct investment estimated between $500-700 million during the partial FY 2025-26. This strategic move not only circumvents tariffs but also strengthens Hetero's presence in the lucrative U.S. market.

The recent India-European Union Free Trade Agreement (FTA), concluded in January 2026, eliminates tariffs on Indian pharmaceuticals entering the EU. This development enhances Hetero's competitiveness in the European market, providing a significant boost to its export potential. However, compliance with the EU's Falsified Medicines Directive remains imperative, necessitating stringent quality controls and traceability measures to maintain market access.

Hetero Labs Limited — Regulatory Compliance & Quality Standards

Regulatory compliance is paramount for Hetero's sustained success in international markets. In October 2025, the U.S. Food and Drug Administration (FDA) issued a Form 483 to Hetero's Nakkapalli facility in Andhra Pradesh, citing six major compliance lapses, including quality control deficiencies and improper documentation practices. Such observations can jeopardize Hetero's ability to supply APIs and antiretroviral drugs to the U.S. market, underscoring the critical need for rigorous adherence to Good Manufacturing Practices (GMP) and prompt corrective actions to address regulatory concerns.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Montelukast shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Hetero Labs Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 58 individual customs records matching Hetero Labs Limited exporting Montelukast, covering 15 formulations to 8 countries via 9 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 138+ countries, 1,324+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Montelukast

Montelukast

Hetero Labs Limited — Montelukast Exporter Profile

Hetero Labs Limited — Montelukast Export Profile: Buyers & Destinations

Where Does Hetero Labs Limited Export Montelukast?

Who Are the Top Buyers of Montelukast from Hetero Labs Limited?

What Is India's Total Montelukast Export Value and How Much Does Hetero Labs Limited Contribute?

What Is the Average Shipment Value for Hetero Labs Limited's Montelukast Exports?

How Does Hetero Labs Limited Compare to Other Indian Montelukast Exporters?

What Montelukast Formulations Does Hetero Labs Limited Export?

How Does Hetero Labs Limited Compare to Nearest Montelukast Exporters?

Which Indian Ports Ship Montelukast Exports?

What Other Respiratory Products Does Hetero Labs Limited Export?

Geopolitical & Trade Policy Impact on Hetero Labs Limited's Montelukast Exports

Hetero Labs Limited — Regulatory Compliance & Quality Standards

About Hetero Labs Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Montelukast Export Data from Hetero Labs Limited

Montelukast Stats

Company Overview

Top Products by Hetero Labs Limited

Related Analysis

Need Detailed Export Data?

Data Source